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Little information is currently available from the various
societies of cardiology on primary percutaneous coronary
intervention (PCI) for acute myocardial infarction (AMI).
Since primary PCI is the main method of reperfusion in AMI
in many centres, and since of all cardiac emergencies AMI
represents the most urgent situation for PCI,
recommendations based on scientific evidence and expert
experience would be useful for centres practising primary
PCI, or those looking to establish a primary PCI
programme. To this aim, a task force for primary PCI in
AMI was formed to develop a set of recommendations to
complement and assist clinical judgment. This paper
represents the product of their recommendations.
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P
ercutaneous coronary intervention (PCI)
refers to a group of invasive procedures that
aim to improve blood flow to the myocar-
dium through the recanalisation of diseased
coronary arteries. Interventions currently used
in clinical practice include plain old balloon
angioplasty (POBA), intracoronary stenting,
coronary atherectomy, and thrombectomy.
PCI techniques, in conjunction with appro-
priate adjunct pharmacological medications,
have been developed and studied in specific
clinical situations, including acute myocardial
infarction (AMI). Several studies have shown
that primary PCI is preferable to intravenous
thrombolysis for the treatment of AMI.1–5
However, little information is available on
primary PCI for AMI from the various cardiology
societies. For example, the European Society of
Cardiology (ESC) guidelines on AMI, which have
been updated very recently, deal only briefly with
PCI, and do not take into account recent
developments in technology and medical treat-
ment.6 7 The new ESC guidelines discuss indica-
tions and contraindications for PCI in AMI, and
state that PCI is superior to fibrinolysis; however,
they do not detail the specificities and technical
aspects of primary PCI. Our opinions extend the
scope of the official guidelines and provide some
additional updated information dedicated to
mechanical reperfusion. Recent guidelines on
PCI have been published by the American Heart
Association/American College of Cardiology
(AHA/ACC), but they deal only briefly with
AMI.8 No European recommendations are cur-
rently available concerning PCI.
Since primary PCI is the mainstay of reperfu-
sion in AMI in many centres, and since of all
cardiac emergencies AMI represents the most
urgent situation for PCI, recommendations based
on scientific evidence and expert experience
would be useful for centres practising primary
PCI or those looking to set up a primary PCI
programme. Therefore, a group of European
interventional cardiologists formed a task force
to provide recommendations on this subject. This
paper presents the product of their recommenda-
tions for all types of PCI in patients with acute ST
elevation myocardial infarction (MI). The pre-
sent recommendations do not deal with pain
relief, antiarrhythmic drugs, discharge medica-
tions, secondary prevention, rehabilitation, or
any other topic that would overlap with the
official recommendations of the ESC. They focus
mainly on the practical and technical aspects
of management within the catheterisation
laboratory.
These recommendations are intended for
specialists who possess the necessary knowledge,
experience, and skills to perform PCI, and who
work in environments where the necessary
resources and facilities are available; they are
intended to complement and assist clinical
judgment.
METHODS
The task force comprised eight interventional
cardiologists, all based at high volume interven-
tional centres, from eight European countries. A
high volume centre is classified as a centre where
more than 33 primary angioplasty procedures are
performed per year. The task force met in 2002 to
produce a set of recommendations on the use of
PCI for the treatment of AMI. Where significant
Abbreviations: ACT, activated clotting time; ACC,
American College of Cardiology; AHA, American Heart
Association; ACE, angiotensin converting enzyme; AMI,
acute myocardial infarction; CABG, coronary artery
bypass graft; ERV, emergency revascularisation; Gp,
glycoprotein; IMS, initial medical stabilisation; IABP,
intra-aortic balloon pump; LV, left ventricular; LVEF, left
ventricular ejection fraction; LMWH, low molecular weight
heparin; MI, myocardial infarction; PCI, percutaneous
coronary intervention; PTCA, percutaneous transluminal
coronary angioplasty; POBA, plain old balloon
angioplasty; SVG, saphenous vein graft; TVR, target
vessel revascularisation; t-PA, tissue plasminogen
activator; UFH, unfractionated heparin.
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data have been published after the meeting of the task force,
the relevant papers have been referenced in this document.
Hence, these recommendations are current as of December
2002.
These recommendations are a product of evidence and
experience. Although some of the recommended techniques
may be relatively new and largely unsupported by published
data, on the basis of experience and current research, they
are considered by the panel to represent important new
developments.
Where available, evidence from randomised clinical trials
was used to formulate these recommendations. However, the
fast pace of advances in both technology and adjunctive
pharmacotherapy in this area means that complete and
reliable supportive data were not always available.
When lack of evidence or experience made it impossible to
reach a consensus, discussions identify key points to help the
physician through the decision making process.
PCI IN AMI
Indications for PCI in AMI
Background
PCI is an effective procedure for re-establishing coronary
artery perfusion in AMI that gives very good short term (six
month) and long term (five year) outcomes.9 10 Where
facilities are available, most AMI patients are candidates for
PCI.8 Where facilities are not rapidly available, PCI remains a
valid option when thrombolysis is contraindicated or has
failed, as well as in patients with cardiogenic shock. A recent
review of 23 randomised trials comparing PCI and thrombo-
lytic treatment concluded that PCI is a more effective
reperfusion therapy than thrombolysis for treatment of ST
segment AMI.6
Recommendations
When performed by experienced operators, we strongly
recommend PCI as the reperfusion strategy of choice for
patients with AMI. An experienced operator is one who
performs at least 75 angioplasty procedures, of any type, per
year.8
When thrombolysis is contraindicated or has failed, or
when patients are in cardiogenic shock, rapid transfer to a
secondary unit should be ensured. A secondary unit is a unit
with primary angioplasty facilities.
Timing
Background
The value of PCI for AMI, as with thrombolysis, is time
dependent, although the benefits extend beyond the ther-
apeutic window for thrombolysis. The benefit of reperfusion
with primary PCI appears to be present over the first six
hours after the onset of chest pain, and a time window of 12
hours between onset of chest pain and PCI is usually
accepted.
In the PAMI 2 trial, mortality was lowest among patients
treated within two hours of symptom onset, but was
relatively independent of time to therapy after 2 hours.11
Brodie et al evaluated the importance of time to reperfusion
for outcomes after primary angioplasty in 1352 patients.12
They found that very early reperfusion (, 2 hours) was
associated with lower 30 day and late mortality rates
compared with later (> 2 hours) reperfusion (4.3% at , 2
hours v 9.2% at > 2 hours; p = 0.04); 30 day mortality and
late mortality were relatively independent of time to
reperfusion in patients with reperfusion times > 2 hours
(9.0% at 2–4 hours, 9.3% at 4–6 hours, and 9.5% at . 6
hours). A time to reperfusion of , 2 hours was also
important for the recovery of left ventricular (LV) func-
tion.12 These data correspond to post hoc analyses, since
randomisation was not carried out as a function of time.9 10
Antoniucci et al also found a relationship between time to
treatment and mortality in a real world population.13
Zijlstra et al found that the combined rate of death, non-
fatal reinfarction, and stroke remained relatively stable with
increasing time to reperfusion in 1302 patients treated by
primary angioplasty (5.8% at , 2 hours, 8.6% at 2–4 hours,
and 7.7% at . 4 hours).14 Follow up in the STENT PAMI trial
showed a higher incidence of re-occlusion and reinfarction in
the late perfusion group (> 6 hours), although time to
reperfusion had no effect on mortality in this study.15
Likewise, in the 29 080 patients in NRMI 2, mortality was
independent of the delay between symptom onset and
hospital admission over a wide range from , 2 hours to
. 12 hours.16 However, mortality was linked to door to
balloon time, with a significant increase in mortality when
door to balloon times exceeded 2 hours.
Recommendations
We strongly recommend that PCI for AMI is performed
swiftly, with a door to balloon time of , 2 hours.
When AMI is diagnosed at a primary unit (a unit without
primary angioplasty facilities), we recommend that the time
taken to transport the patient to a centre with interventional
capabilities should be used to prepare the cardiac catheter-
isation laboratory and to alert all personnel involved. The
patient should be directed to the cardiac catheterisation
laboratory without any delay in the Accident and Emergency
department. Crucial time can be saved by ensuring the
presence of a guide to direct the ambulance crew on arrival.
Transfer
Background
When patients present to a primary unit without interven-
tional capabilities, a decision needs to be made regarding
appropriate treatment. The principal therapeutic options in
such a situation are either thrombolysis, or transfer to a
facility with a cardiac catheterisation laboratory (with or
without adjunctive therapy). Any such transfer needs to be
effected rapidly to take advantage of the early benefits of
revascularisation.
Vermeer et al investigated the safety and feasibility of acute
transport followed by rescue PCI or primary PCI in patients
with AMI initially admitted to a hospital without PCI
facilities.17 Patients were randomised to three groups:
thrombolysis (alteplase); thrombolysis followed by transfer
and rescue PCI; or transfer and primary PCI. The differences
in death or recurrent infarction within 42 days in the three
groups were not significant but it was concluded that acute
transfer for rescue PCI or primary PCI in patients with
extensive AMI is feasible.
The PRAGUE study assessed patients with AMI presenting
within six hours of symptom onset to primary units without a
cardiac catheterisation laboratory. Immediate transportation
for primary angioplasty was demonstrated to be more
effective than thrombolysis (streptokinase) during transpor-
tation for angioplasty or thrombolysis (streptokinase) alone
in reducing the frequency of the combined end point of
death, reinfarction, or stroke at 30 days (8% v 15% v 23%;
p , 0.02).18 The incidence of re infarction was also notably
reduced by transport for primary angioplasty (1% v 7% v 10%;
p , 0.03). This was recently confirmed in the PRAGUE 2
study, which compared immediate thrombolysis (streptoki-
nase) with transport to a PCI centre.19 Mortality rates at 30
days were 10.4% in the immediate thrombolysis group, and
6.0% in the PCI group (p , 0.05).19
In the DANAMI 2 trial, a large multi-centre, randomised
study, transfer of AMI patients for PCI was compared with
on-site thrombolytic therapy using a 100 mg dose of tissue
2 of 13 Montalescot, Andersen, Antoniucci, et al
www.heartjnl.com
 group.bmj.com on September 15, 2011 - Published by heart.bmj.comDownloaded from 
plasminogen activator (t-PA).20 Among the inclusion criteria,
transfer time from referral hospitals to arrival in the
catheterisation laboratory at the interventional treatment
centre had to be , 3 hours. Ninety six per cent of patients
were transferred within two hours. The median transfer
distance was 50 km (range 3–150 km). The cumulative event
rate (death, MI, or stroke) was 8.0% for patients receiving
PCI, and 13.7% for patients receiving fibrinolysis
(p = 0.0003).21 These results are supported by data from
the recently published AIR PAMI study, in which on-site
thrombolysis was compared with transfer for PCI.22 At 30
days, a 38% relative reduction in major adverse cardiac events
was observed for the transfer group (8.4% v 13.6%, p = NS).
In the recently published CAPTIM trial, transfer of patients
for primary angioplasty was compared with pre-hospital
thrombolysis.23 Patients randomised to the thrombolytic arm
received thrombolytic therapy in the ambulance (and rescue
PCI when required). Patients randomised to primary angio-
plasty received aspirin and heparin during transport. There
were no differences between the two groups in 30 day
mortality, reinfarction, or bleeding complications.
Recommendations
We strongly recommend the transfer of AMI patients to
cardiac catheterisation laboratories if the expected time to
arrival is likely to be ( 2 hours. Transport to an invasive
centre should ideally use the same ambulance stretcher and
crew. On arrival at the secondary unit, the patient should be
taken directly to the cardiac catheterisation laboratory,
bypassing the accident and emergency department.
If a patient undergoing thrombolytic therapy does not have
signs of reperfusion 90 minutes after starting thrombolytics
(persistent chest pain and ST elevation), transfer for rescue
PCI as quickly as possible should be considered.
Centres and operators
Background
Data from NRMI indicate that mortality rates in patients
undergoing primary PCI for AMI are lowest in centres
performing large numbers of procedures.24 There is a 28%
lower mortality rate in centres carrying out the most PCI
procedures (. 33 per year) compared with those performing
the least (, 12 per year), representing two fewer deaths per
100 patients treated. In NRMI 2, higher volume centres were
also associated with improved outcomes.24
The ACC/AHA guidelines recommend that PCI for AMI
should be performed in high volume centres (. 400 cases per
year) with fully equipped interventional laboratories, experi-
enced support staff, and on-site cardiac surgery teams (all
available around the clock).8
However, these requirements effectively preclude a large
eligible population from receiving PCI for AMI, which under
appropriate circumstances (see above) is associated with
improved outcomes compared with thrombolysis. Given that
the rate of complications requiring immediate cardiac surgery
intervention (abrupt closure, dissection, or perforation) is
low (0.1% for perforation25), the C-PORT study (n = 451)
was set up to investigate whether primary PCI is superior to
thrombolytic therapy for the treatment of AMI in primary
units.26 All sites were required to complete a formal primary
PCI development programme before randomising patients
into the study. This programme consisted of setting
standards, training staff, developing logistics, and creating
a quality and error management programme.26 The pro-
gramme lasted approximately three months and was tailored
for each institution.26
The combined incidence of death, repeat MI, or strokes was
reduced in the PCI group at six weeks (10.7% v 17.7%;
p = 0.03) and six months (12.4% v 19.9%; p = 0.03).26 In
addition, the mean duration of hospital stay was shorter in
the PCI group than the thrombolytic group (4.5 v 6 days;
p = 0.02).26 These data show that primary PCI for AMI is
superior to thrombolytic therapy, and indicate that primary
PCI capabilities can be developed successfully in hospitals
lacking cardiac surgery back up. However, patients at high
risk or with complex coronary anatomy were excluded from
the trial.
Wharton et al found that primary angioplasty in high risk
AMI patients in hospitals without cardiac surgery facilities
was safe and effective, with excellent acute and six month
outcomes that compared favourably to those reported from
high volume surgical centres.27 The combined primary end
point of death, reinfarction, and cerebrovascular accident
occurred in 4.3% of patients at 30 days, and in 7.2% of
patients at six months.27
Recommendations
PCI should ideally be performed in high volume centres
(. 33 primary PCI procedures per year) with fully equipped
interventional laboratories and experienced support staff
(both available around the clock). In addition, all operators
should be properly trained, possess appropriate technical
skills, and have acceptable levels of experience to achieve
short door to balloon times.8
Considering the high risks associated with many of these
urgent procedures, we recommend that a complete and well
trained team of nurses and, wherever possible, two physi-
cians should be present in the catheterisation laboratory
throughout the procedure: one senior interventional cardiol-
ogist for the PCI procedure, and one physician to monitor the
patient’s haemodynamic, respiratory, and, if necessary,
anaesthetic state.8 The lack of available data on this topic
led to this recommendation from the group based on their
expert opinion. The authors acknowledge that many centres
use only one physician in the room. However, a single
physician cannot manage the most difficult cases with
complete safety (cardiac arrest, cardiogenic shock, need for
intubation or ventilation during the procedure), this issue
being mainly related to night time.
As demonstrated in the C-PORT study, good outcomes can
be achieved in hospitals without cardiac surgery support,
given successful completion of a PCI training programme and
appropriate selection of cases.26
A broad range of catheters, guidewires, stents, and
supportive devices, such as intra-aortic balloon pumps
(IABP), should be available.
TECHNICAL ASPECTS
Balloons versus stents
Background
The STENTIM 1 study demonstrated that coronary stenting
in AMI is feasible and safe.28 The STENT PAMI pilot trial
showed that routine stent implantation during mechanical
reperfusion of AMI is associated with favourable event-free
survival and low rates of restenosis.29
Several studies have shown the advantages of stenting over
balloon angioplasty for AMI. The FRESCO,30 GRAMI,31
Zwolle,10 PASTA,32 and STENTIM 233 trials directly compared
stenting with balloon angioplasty and demonstrated the
benefits of stenting over PCI in reducing major events after
the procedure. This was mainly because of a reduced need for
repeat revascularisation procedures rather than a reduction
in death and reinfarction rates. PASTA showed that primary
stent implantation in selected patients with AMI resulted in a
lower incidence of major cardiac events during the first 12
months post-procedure and a lower six month restenosis rate
than primary balloon angioplasty.34 The Zwolle trial showed
better long term clinical outcomes with stenting at 24 months
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versus balloon angioplasty.34 The CADILLAC trial showed that
routine stent implantation in AMI patients resulted in higher
rates of event-free survival and better angiographic outcomes
than PCI.35
Care should always be taken to avoid the undersizing of
balloons and stents, since this is associated with worse
outcomes. Undersizing may be more frequent in AMI
patients than in those without AMI because of low flow,
reduced output, and vasoconstriction. Repeated intracoron-
ary glyceryl trinitrate (nitroglycerin) injections may be
helpful to enable accurate judgment of vessel size.
Recent developments
The technique of direct stenting (implanting a stent without
balloon pre-dilatation) has recently emerged as a potential
interventional option. When compared with conventional
stenting, direct stenting in AMI patients reduced the
incidence of angiographic no reflow, thereby increasing
ultimate effective myocardial reperfusion.36 Loubeyre et al
randomised selected patients with AMI to direct stenting or
conventional stent implantation. They found direct stenting
to be safe and effective, with less slow flow or no reflow at
the end of the procedure and better ST segment resolution.37
Direct stenting can be safely applied in patients where the full
extent of the lesion is clearly visible.
Drug eluting stents have emerged to challenge conven-
tional interventional approaches, and have demonstrated low
rates of restenosis at follow up in patients with stable
coronary disease.38 In the RAVEL trial, the overall rate of
major cardiac events was reduced at one year follow up by
the use of a sirolimus coated stent compared with a standard
stent (5.8% v 28.8%; p , 0.001). This difference was because
of a higher rate of target vessel revascularisation in the
standard stent group. However, as yet, the new sirolimus and
paclitaxel eluting stents have not been tested in AMI.
Recommendations
We strongly recommend the use of stents for AMI and the
use of direct stenting whenever possible.
Balloon counterpulsation
Background
The use of IABPs is a useful supportive therapy in patients
with cardiogenic shock (reviewed in Bates et al39). Their use in
AMI has been evaluated in a randomised study, which
showed that careful use of prophylactic aortic counter-
pulsation can prevent re-occlusion of the infarct related
artery, and can improve overall clinical outcomes in patients
undergoing acute cardiac catheterisation during MI.40
The effectiveness of IABPs depends on heart rate and sinus
rhythm (atrial fibrillation, ventricular tachycardia, other
tachydysrhythmias, and the presence of aortic regurgitation
can impair their function), as well as ‘‘driving’’ mean aortic
pressure. The size of these devices can present some
difficulties with tortuous anatomy, but newer versions
continue to improve the utility of this therapy.
Recommendations
IABPs should be available in the cardiac catheterisation
laboratory at the time of the intervention; bringing an IABP
from the surgical theatre once the procedure has started is
not a reliable option. The use of IABPs is strongly
recommended in patients with AMI complicated by cardio-
genic shock.
Arterial access
Background
Three arterial access approaches are used in PCI: femoral,
brachial, and radial. The femoral approach is more commonly
used, but the brachial and radial approaches have the
advantage of allowing immediate post-procedural ambula-
tion.
A randomised comparison of transradial, transbrachial,
and transfemoral PCI with 6 French guiding catheters (the
Access Study) showed that the three techniques have
comparable results in experienced hands; procedural and
clinical outcomes of PCI were similar for the three
subgroups.41 However, major access site complications were
more frequently encountered after transbrachial and trans-
femoral PCI.
Transradial PCI in AMI is associated with fewer severe
access site related bleeding complications than the trans-
femoral approach, which is particularly relevant in patients
who may be receiving thrombolytics or glycoprotein (Gp) IIb/
IIIa inhibitors.42 Nevertheless, it should be noted that access
failure is slightly more frequent during transradial PCI,43 and
that sheath sizes are usually limited to 6 or 7 French. Difficult
AMI cases, such as shock or coronary artery bypass grafting
(CABG) patients, are not optimal candidates for radial access.
Recommendations
The radial approach combines the advantages of decreased
bleeding complications and early ambulation, and hence is
likely to offer significant clinical safety benefits and cost
savings. However, radial access is a good option only in
centres already routinely using this approach for elective
cases.
Closure devices
Background
Closure devices currently in use include collagen plug devices
(AngioSeal, VasoSeal), percutaneous suture closure devices
(Perclose), and external aids to manual compression
(Femostop). In elective angioplasty, these devices enable
early patient discharge; however, this is less of a concern in
AMI patients.
A large study comparing AngioSeal, Perclose, and manual
compression in PCI showed a similar overall risk with both
devices compared with manual compression.42 A trial
comparing VasoSeal and Perclose with Femostop showed
that VasoSeal and Perclose were at least as safe as Femostop,
with similar late complications.44
Some of these devices are associated with specific risks;
furthermore, the small percentage of patients in whom these
devices fail are likely to develop more severe bleeding
complications.
Recommendations
We do not recommend the systematic use of closure devices
in AMI patients. When the physician is experienced in the
use of closure devices, the use of such devices should be left
to their discretion.
New developments: thrombectomy and distal
protection devices
Background
A variety of devices have been developed in an attempt to
reduce microvascular embolisation during balloon dilatation
and/or stenting in AMI patients. However, to date, there are
few published randomised studies regarding the use of these
devices, and none specifically in ST segment elevation MI
patients.
The X-Sizer is an atherectomy and thrombectomy device
designed to aspirate excised atheroma, thrombus, and debris.
Angiographic analysis of the first cohort of human subjects
suggests that X-Sizer helical atherectomy is a feasible method
for removing thrombus and is associated with a low rate of
angiographic complications.45 A randomised study found no
significant increase in time to balloon dilatation in patients
treated with X-Sizer and, although no significant difference
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in TIMI grade 3 flow was seen between the groups,
examination of the microcirculation using corrected TIMI
frame counts showed lower counts (higher flow rates) in
X-Sizer treated patients.46 Use of the X-Sizer also resulted in
significantly lower ST segment scores (a predictor of LV
function recovery) at six hours post-procedure compared
with PCI alone. Recently presented data from the randomised
X-tract (thrombotic lesions and saphenous vein grafts) and
X-amine (AMI) trials suggest that the use of the X-Sizer in
thrombotic lesions improves flow and possibly also out-
comes.47 48 Encouraging preliminary results have also been
reported with the Rescue percutaneous thrombectomy (PT)
catheter in AMI, which aspirates thrombus in conjunction
with a suction pump.49
The Acolysis system is an ultrasonic, catheter based device
that uses high frequency sound waves to dissolve blood clots.
Results from the Acolysis Registry indicated that Acolysis led
to successful recanalisation (TIMI grade 2–3) in 75% of
patients.50
The Angiojet Rheolytic Thrombectomy system is a catheter
based device that uses a high speed saline jet to create a
vacuum to break up and then suck out the blood clot. It is
currently being evaluated in the AIMI trial, which aims to
compare final infarct size and clinical and angiographic
outcomes in AMI patients treated with rheolytic thrombec-
tomy followed by immediate PCI versus primary PCI alone
(without thrombectomy).
Distal protection devices
Distal protection devices have been developed to prevent
distal embolisation of microparticles. It has been postulated
that microembolisation is the primary cause of adverse
events, such as MI and the no reflow phenomenon, during
interventional procedures in saphenous vein grafts (SVGs).51
New catheter systems, such as the PercuSurge,
Angioguard, and Filterwire devices, have been developed to
contain and retrieve microparticles, thus protecting against
distal embolisation. The randomised SAFER study showed
that the PercuSurge device was associated with a significant
50% reduction in major adverse events, compared with
stenting alone during elective PCI on diseased SVGs.52 The
ongoing, multicentre, prospective, randomised EMERALD
study aims to assess PercuSurge specifically in AMI patients.
Five hundred patients will be enrolled in the study, with half
randomised to PCI with PercuSurge and half randomised to
PCI without embolic protection.
Recommendations
A possible complication with thrombectomy and distal
protection devices is the danger that they may dislodge
thrombus during delivery. Furthermore, current devices are
large and difficult to deploy.
Specific, randomised, adequately sized trials in AMI
patients are required before the use of these devices in
patients with AMI can be recommended on a routine basis.
ADJUNCT PHARMACOLOGICAL TREATMENT
Antiplatelet agents
Background
Platelet activation is a major determinant of the risk of
subacute stent thrombosis following stent placement, and
antiplatelet therapy is an important adjunctive treatment to
reduce ischaemic complications in patients undergoing PCI.
Aspirin
Aspirin reduces the frequency of ischaemic complications
after coronary angioplasty and is widely accepted and used.8
The minimum effective dosage in PCI for AMI has never been
established.
Thienopyridines
The thienopyridines, ticlopidine and clopidogrel, inhibit ADP
induced platelet activation and are also widely used during
PCI. The standard loading dose of clopidogrel tested in
randomised studies of unstable angina and coronary stenting
is 300 mg, followed by 75 mg daily.53–55 The only concern that
exists with regard to the early administration of clopidogrel is
in patients who have to undergo urgent surgery (a very rare
situation) who may require platelet transfusions and/or the
use of drugs such as aprotinin. High loading doses of
clopidogrel (600 mg) cause very pronounced platelet inhibi-
tion, reaching peak concentrations two hours after adminis-
tration and lasting for two days.56 A high loading dose of
clopidogrel (450 mg) followed by 75 mg per day plus aspirin
has been shown to be superior to aspirin plus standard
clopidogrel (75 mg) or ticlopidine (250 mg twice daily) in
inhibiting platelet aggregation.57 However, these studies were
small, were not powered to detect clinical differences, and did
not involve AMI patients. The benefit of thienopyridine pre-
treatment with ticlopidine or clopidogrel has been shown in
elective stenting with or without GpIIb/IIIa antagonists.58 59
This kind of pre-treatment is limited in primary PCI for AMI
by the short period of time preceding PCI (transfer time);
however, the accelerated antiplatelet effect of clopidogrel
may be beneficial in AMI patients undergoing PCI, possibly
by improving the patency rate. This hypothesis is being
investigated in the CLARITY study, which is enrolling AMI
patients treated with a thrombolytic agent. Finally, consider-
ing the high rate of stenting in patients undergoing primary
PCI for AMI (approximately 95%), clopidogrel treatment is
necessary, and administration as early as possible seems
appropriate.
Although the thienopyridines, in combination with aspirin,
achieve a significant antiplatelet effect, this combination is
not sufficient to reduce platelet dependent restenotic
processes.
GpIIb/II Ia inhibitors
The binding of fibrinogen and other adhesive proteins to
adjacent platelets via the GpIIb/IIIa integrin serves as the
final common pathway of platelet thrombus formation. A
large number of trials have demonstrated that GpIIb/IIIa
inhibitors reduce the frequency of ischaemic complications
during and after PCI.
In the RAPPORT trial, platelet inhibition with abciximab
during primary PCI for AMI led to a reduction in death,
reinfarction, and urgent target vessel revascularisation (TVR)
at 30 days and six months.60 However, this benefit was
associated with an increased risk of bleeding in the
abciximab treated group and no effect on the composite
end point of death, reinfarction, and any revascularisation at
six months.60
In the ISAR 2 trial, in addition to its effects on vessel
patency, abciximab improved the recovery of microvascular
perfusion, and enhanced the recovery of contractile function
in the area at risk after PCI in AMI patients.61 The rate of
major adverse cardiac events was substantially reduced at 30
days.62 However, angiographic restenosis at one year follow
up was not reduced.
In the double blind ADMIRAL trial, early administration of
abciximab in AMI (before sheath insertion in all patients and
before reaching the catheterisation laboratory in 26% of
patients) was associated with improvements in: coronary
patency before stenting; the success rate of the stenting
procedure; coronary patency at six months; LV function; and
clinical outcomes at 30 days and six months compared with
placebo, without an excess of major bleeding.63 A substudy of
this trial showed that abciximab dramatically reduced
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platelet aggregate size and increased fibrin accessibility in ex
vivo platelet rich clots in AMI patients.64
In the CADILLAC trial of patients undergoing POBA or
stenting for AMI, abciximab reduced the rates of subacute
thrombosis and recurrent ischaemia leading to repeat target
lesion revascularisation, as well as the composite clinical end
point of death/MI/urgent revascularisation at one month, but
failed to reduce late cardiac events including restenosis at one
year.35
The ACE trial compared infarct related artery stenting
(using a Carbofilm coated stent) and abciximab with infarct
related artery stenting (using a Carbofilm coated stent) alone
in AMI patients. There were no enrolment restrictions based
on age, clinical status on presentation (cardiogenic shock
patients were enrolled), or high risk coronary anatomy. The
primary end point of major adverse cardiac events at 30 days
was significantly reduced in the abciximab arm (a multi-
variate analysis showed that abciximab had an independent
protective effect). Furthermore, abciximab significantly
reduced ST segment elevation; there was no difference
between the two treatment arms in terms of bleeding
complications.65
Finally, all five clinical trials testing abciximab in primary
angioplasty showed significant reductions in ischaemic
events at 30 days. The lack of late benefit observed in the
subgroup of stented patients in the CADILLAC study is in
contrast with the other studies, and may be because of the
following: play of chance in subgroup analysis of a study with
a factorial design; clinical and angiographic selection of
patients; use of a low risk patient population; late adminis-
tration of the drug; no adjudication of events; or drug cross
over in an open study.
A meta-analysis of these five AMI trials showed a
significant reduction in death or MI at 30 days and a
favourable trend towards a reduction in mortality. Together
with earlier trials of abciximab in the absence of AMI
(including EPILOG,66 EPIC,67 EPISTENT,68 and ERASER69), a
significant mortality reduction is achieved with this agent.70
Eptifibatide, a small molecule GpIIb/IIIa inhibitor, has also
been investigated in AMI patients. In a non-randomised
study, eptifibatide was administered to AMI patients in the
emergency room before primary angioplasty, and resulted in
a higher incidence of partial or complete reperfusion
compared with patients administered eptifibatide at the time
of the procedure.71 A randomised controlled trial of eptifiba-
tide versus combination therapy with eptifibatide and lytics is
in progress (ADVANCE MI).
The efficacy of tirofiban, another small molecule GpIIb/IIIa
inhibitor, in patients undergoing PCI for AMI has been
investigated in the randomised, open label TIGER PA pilot
study.72 Tirofiban was given as a bolus (10 mg/kg over three
minutes) and infusion (0.15 mg/kg/min for 24 hours) in the
emergency room before each patient was brought to the
cardiac catheterisation laboratory; a control group received
tirofiban in the cardiac catheterisation laboratory. A better
patency rate was reported in the group that received the drug
early.72
Recommendations
Aspirin should be given as early as possible, with a
recommended starting dose . 160 mg; a high dose adminis-
tered intravenously is preferable.
A loading dose of 300–600 mg of clopidogrel is recom-
mended before intervention (given the prevalence of stenting
in interventional procedures, . 90%). The patient should be
continued on at least 75 mg of clopidogrel once daily for at
least one month after stent PCI.
To date, abciximab is the only GpIIb/IIIa inhibitor proven
to be clinically effective in PCI for AMI.35 60 62 63 65 Immediate
administration of abciximab on first presentation is recom-
mended for AMI patients scheduled for primary PCI.
Anticoagulants
Background
Various anticoagulant drugs are available.
Unfractionated heparin (UFH)
When planning appropriate anticoagulation for a PCI
procedure, consideration should be given to the anticipated
transfer time and duration of the procedure, and the
anticoagulation regimen should be adjusted accordingly.
Furthermore, each patient’s response to anticoagulation is
different. UFH prevents clot formation at the site of arterial
injury and on coronary guidewires and catheters used during
PCI.8 It is routinely given during PCI for AMI. Measurement
of the activated clotting time (ACT) is useful for monitoring
heparin therapy during coronary angioplasty.73 Few prospec-
tive clinical data are available to define the optimal level of
anticoagulation during PCI.
The ACC recommends that, in those patients who do not
receive GpIIb/IIIa inhibitors, sufficient UFH should be given
during coronary angioplasty to achieve an ACT of 250–300
seconds with the HemoTec device and 300–350 seconds with
the Hemochron device. Weight adjusted bolus heparin (70–
100 IU/kg) can be used to avoid excess anticoagulation. If
target ACT values are not achieved after a bolus of heparin
has been administered, additional heparin boluses (2000–
5000 IU) can be given. Early sheath removal should be
performed when the ACT falls to , 150–180 seconds. The
UFH bolus should be reduced to 50–70 IU/kg when GpIIb/IIIa
inhibitors are given, in order to achieve a target ACT of 200
seconds using either the HemoTec or the Hemochron device.
The currently recommended target ACT for eptifibatide and
tirofiban is , 300 seconds during coronary angioplasty. Post-
procedural heparin infusions are not recommended during
GpIIb/IIIa treatment.8
A recent meta-analysis of six randomised trials of novel
adjunctive anti-thrombotic regimens for PCI identified an
optimal ACT of 350–375 seconds for patients undergoing PCI
without GpIIb/IIIa inhibitors.74 In subgroups at a greater risk
of thrombotic events, a steeper gradient of benefit between
lower and higher levels of ACT is evident.70 When using a
GpIIb/IIIa inhibitor, a low dose of UFH (70 U/kg) is effective
and safe.74
Low molecular weight heparins (LMWH)
LMWHs, such as enoxaparin, have significant advantages
over UFH; they yield a more predictable and stable anti-
coagulant response than UFH and require no monitoring. The
NICE 1 and NICE 4 trials investigated enoxaparin with and
without abciximab in PCI, and demonstrated a low/minor
incidence of bleeding and infrequent major cardiac events at
30 days.75 Similar positive experiences have been reported
with lower doses of LMWH.76 77 The randomised, double blind
REDUCE trial failed to show a benefit in restenosis with the
LMWH reviparin, but showed a significant reduction in early
ischaemic events with reviparin compared with UFH.78
Optimal dosing regimens for the administration of LMWH
at the time of primary PCI have yet to be determined.
However, the use of LMWH in AMI has been shown to be
associated with reduced ischaemic complications compared
with UFH in large randomised thrombolytic trials,79 80 and is
currently being investigated in two primary PCI trials
(ADVANCE MI and FINESSE).
Patients who have received enoxaparin before the onset of
ST segment elevation MI (1 mg/kg, twice daily, subcutaneous
dose) do not require further administration of the drug if PCI
is performed within 8 hours. Similarly, patients who would
have received an ASSENT 3 regimen of enoxaparin after the
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onset of symptoms do not require any additional anti-
coagulation in the catheterisation laboratory.81 82
Direct thrombin inhibitors
Direct thrombin inhibitors such as bivalirudin, are a new
class of anticoagulant. Bivalirudin has been investigated in
the CACHET,83 REPLACE 1,84 and REPLACE 285 studies in the
setting of elective PCI. Direct thrombin inhibitors have yet to
be investigated in patients with AMI.
Recommendations
We recommend the administration of heparin at a dosage
adjusted to weight and/or ACT. We recommend 70 U of UFH
per kg in patients undergoing PCI with adjuvant GpIIb/IIIa
inhibitors. If higher doses of UFH are considered, the use of
GpIIb/IIIa inhibitors is associated with a risk of over-
anticoagulation.
Substitution of LMWH for UFH appears promising, but
firm recommendations cannot be given at this time. Patients
receiving enoxaparin (ASSENT 3 regimen) do not require any
additional anticoagulation when they reach the catheterisa-
tion laboratory.
Trial acronyms
N ACCESS: A Comparison of Percutaneous Entry Sites for
Coronary Angioplasty
N ADMIRAL: Abciximab before Direct Angioplasty and
Stenting in Myocardial Infarction Regarding Acute and
Long term Follow up
N ADVANCE MI: Addressing the Value of Facilitated
Angioplasty after Combination Therapy or Eptifibatide
Monotherapy in Acute Myocardial Infarction
N AIMI: AngioJet Rheolytic Thrombectomy in Patients
Undergoing Primary Angioplasty for Acute Myocardial
Infarction
N AIR PAMI: Air Primary Angioplasty in Myocardial
Infarction
N AMISTAD: Acute Myocardial Infarction Study of
Adenosine
N ASSENT: Assessment of the Safety and Efficacy of a
New Thrombolytic
N ATLAS: Acolysis during Treatment of Lesions Affecting
Saphenous Vein Bypass Grafts
N CACHET: Comparison of Abciximab Complications
with Hirulog for Ischemic Events Trial
N CADILLAC: Controlled Abciximab and Device
Investigation to Lower Late Angioplasty Complications
N CAPTIM: Comparaison de l’Angioplastie Primaire et de
la Thrombolyse Prehospitaliere a la Phase Aigue de
l’Infarctus du Myocarde
N CARESS: Carotid Revascularization With Endarterec-
tomy or Stenting Systems
N CLARITY: Clopidogrel as Adjunctive Reperfusion Therapy
N C-PORT: Atlantic Cardiovascular Patient Outcomes
Research Trial
N DANAMI: Danish Acute Myocardial Infarction Study
N EMERALD: Enhanced Myocardial Efficacy and
Recovery by Aspiration of Liberalized Debris
N EPIC: Evaluation of c7E3 for Prevention of Ischemic
Complications
N EPILOG: Evaluation of PTCA to Improve Long term
Outcome with Abciximab GpIIb/IIIa Blockade
N EPISTENT: Evaluation of Platelet IIb/IIIa Inhibitor for
Stenting Trial
N ERASER: Evaluation of ReoPro and Stenting to
Eliminate Restenosis
N ESCG: European Cooperative Study Group for rt-PA in
Acute Myocardial Infarction
N FINESSE: Facilitated Intervention With Enhanced
Reperfusion Speed To Stop Events
N FRESCO: Florence Randomized Elective Stenting in
Acute Coronary Occlusions
N GRACIA: Grupo de Analisis de la Cardiopatia
Isquemica Aguda
N GRAMI: Gianturco–Roubin in Acute Myocardial
Infarction
N GUSTO: Global Utilization of Streptokinase and t-PA
for Occluded Arteries
N HEAP: Heparin in Early Patency Randomized Trial
N INTEGRITI: Integrilin and Tenecteplase in Acute
Myocardial Infarction
N ISAR 2: Intracoronary Stenting and Antithrombotic
Regimen
N NICE: National Investigators Collaborating on
Enoxaparin
N NRMI 2: National Registry of Myocardial Infarction 2
N PACT: Plasminogen-activator Angioplasty Compati-
bility Trial
N PAMI: Primary Angioplasty in Acute Myocardial
Infarction
N PAMI 2: Second Primary Angioplasty in Acute
Myocardial Infarction
N PASTA: Primary Angioplasty versus Stent Implantation
in Acute Myocardial Infarction
N PRAGUE: Long Distance Transport for Primary
Angioplasty versus Immediate Thrombolysis in Acute
Myocardial Infarction
N RAPPORT: ReoPro and Primary PTCA Organization
and Randomized Trial
N REDUCE: Reduction of Restenosis After PTCA, Early
Administration of Reviparin in a Double-Blind
Unfractionated Heparin and Placebo-Controlled
Evaluation
N REPLACE: Randomized Evaluation in Percutaneous
Coronary Intervention Linking Angiomax to Reduced
Clinical Events
N RESCUE: Randomized Evaluation of Salvage Angio-
plasty with Combined Utilization of Endpoints
N SAFER: Saphenous Vein Graft Angioplasty Free of
Emboli Randomized Trial
N SHOCK: Should We Emergently Revascularize
Occluded Coronaries for Cardiogenic Shock
N SPEED: Strategies for Patency Enhancement in the
Emergency Department
N STENT PAMI: Stent Primary Angioplasty in Myocardial
Infarction
N STENTIM: Stenting in Acute Myocardial Infarction
N SWIFT: Should We Intervene Following Thrombolysis
N TAMI: Thrombolysis and Angioplasty in Myocardial
Infarction
N TIGER PA, Tirofiban Given in the Emergency Room
Before Primary Angioplasty Pilot Study
N TIMI: Thrombolysis in Myocardial Infarction
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SPECIFIC CASES
Facilitated PCI
Background
Facilitated PCI refers to the use of pharmacological treatment
to establish early reperfusion before catheterisation. This
strategy combines the benefits of early revascularisation with
easier intervention, since the artery will already be open in
many patients. Facilitation may be obtained with full dose
GpIIb/IIIa inhibitors, full dose thrombolytics, or a combina-
tion of half dose thrombolytics and full dose GpIIb/IIIa
inhibitors.
Limited data have been published concerning the potential
benefit of high doses of UFH before PCI, with conflicting
results. The randomised HEAP study found no benefit from
high dose heparin as a pre-treatment for primary angioplasty
in AMI compared with low dose or no heparin.86 In a non-
randomised comparison, Zijlstra et al found that pre-hospital
administration of aspirin and heparin in AMI patients
resulted in a higher initial patency of the infarct related
artery than later administration of these two drugs.87
Facili tated PCI with thrombolytic therapy
Conflicting results have been obtained so far with the
combined approach of thrombolytics and PCI versus PCI
alone or thrombolytics alone. Early trials using full dose
thrombolytics produced equivocal results regarding the utility
of post-thrombolytic intervention and, in general, reported an
increased rate of bleeding complications. For example, the
SWIFT,88 TIMI IIA,89 TAMI,90 and ESCG91 trials demonstrated
no mortality benefit (and sometimes unfavourable trends)
from thrombolysis followed by intervention compared with
thrombolysis alone. Similar detrimental data were seen in a
study by Vermeer et al17 and in the PRAGUE 1 trial.18
More recent studies, however, have indicated that throm-
bolysis followed by early intervention may be beneficial. An
observational study investigating immediate angioplasty with
stent implantation after pre-hospital thrombolysis in a non-
selected AMI population found it to be safe, achieving high
and early patency rates.92 The randomised PACT trial
compared primary angioplasty with half dose thrombolytic
(recombinant t-PA) followed by immediate, planned, rescue
angioplasty.93 The primary end point of this study, LV
function at discharge, did not show any improvement from
facilitated PCI. However, early TIMI grade 3 flow was
associated with the preservation of LV function. The recent
GRACIA study reported a significant clinical advantage of
early systematic PCI (within 24 hours) over later ischaemic
driven PCI after thrombolysis.94 95
Facilitated PCI with thrombolytic therapy is being inves-
tigated in the randomised ASSENT 4 trial. The two arms of
the study are: aspirin, UFH, and PCI with GpIIb/IIIa
inhibitors at the physician’s discretion and clopidogrel if
stented; and aspirin, tenecteplase, UFH, and PCI with no
GpIIb/IIIa inhibitor but clopidogrel if stented.
Facili tated PCI with a combination of thrombolytic
therapy and GpIIb/II Ia inhibitors
In the SPEED (GUSTO V pilot) trial, patients were
randomised to standard dose abciximab, standard dose
abciximab with low dose reteplase, or standard dose reteplase
alone.96 All patients had early angiography, and PCI was
encouraged. Early PCI patients showed a procedural success
rate of 88% and a significant reduction in the 30 day
composite incidence of death, reinfarction, or urgent TVR
(5.6% v 16%) compared with patients who did not undergo
early PCI. The early PCI patients had 66.3% TIMI grade 2–3
flow pre-procedure (median time 63 minutes from the
start of thrombolysis) and 97.6% (p , 0.001) TIMI grade
2–3 flow post-PCI. These patients also had fewer bleeding
complications and required fewer transfusions than patients
who did not undergo early PCI (9% v 16%; p = 0.02).
Patients receiving abciximab with half dose reteplase and PCI
showed a trend towards improved 30 day outcomes. Early
facilitated PCI was, therefore, shown to be both feasible and
associated with positive outcomes, especially with the use of
a combination of abciximab with half dose reteplase.97 98
In the TIMI 14 trial, 888 AMI patients were randomised to
full dose alteplase, abciximab alone, or abciximab with
reduced dose alteplase or streptokinase.99 In a group of
patients who underwent adjunctive PCI, a combination
reperfusion regimen of abciximab and half dose thrombolytic
therapy was associated with greater ST segment resolution
than reteplase alone, even after the procedure (51% v 3%).100
Among patients treated with combination therapy and
presenting at angiography with TIMI grade 3 flow, adjunctive
PCI significantly improved ST segment resolution (57% v
24%), reflecting increased tissue and microvascular perfu-
sion.100 Two large trials tested the concept of combined
therapy in AMI (reduced dose thrombolytics and full dose
GpIIb/IIIa inhibitors versus full dose thrombolytics) but
without early intervention.101 102 No firm conclusions can be
drawn from these trials about the benefits of facilitated
angioplasty.
The efficacy of facilitated PCI as a reperfusion strategy is
under investigation in a number of large randomised trials,
including FINESSE, ADVANCE MI, TIGER,72 and CARESS.
FINESSE is a three armed, randomised, multi-centre, double
blind, double dummy trial currently investigating 3000
patients with AMI undergoing primary/facilitated PCI after
receiving either early abciximab alone, early abciximab
plus half dose reteplase, or late abciximab at the time of
PCI. PCIs are performed 60–240 minutes from the time of
randomisation.
ADVANCE MI is a two armed, randomised, multi-centre,
double blind trial currently investigating 6000 patients with
AMI undergoing primary/facilitated PCI after receiving early
eptifibatide alone or early eptifibatide plus half dose
tenecteplase before PCI. There is also a second randomisation
opposing anticoagulation with low dose enoxaparin or low
dose UFH.
CARESS is a randomised, open label, multi-centre trial
investigating 2000 patients with AMI in hospitals without
cardiac catheterisation laboratories. Patients are randomised
to abciximab plus half dose reteplase and transferred to a
referral hospital with a cardiac catheterisation laboratory for
immediate PCI, or are given the same combination therapy
with transfer only as needed for rescue PCI. TIGER has a
similar design using tirofiban and tenecteplase, with anti-
coagulation provided by enoxaparin in both arms.72
Recommendations
Data on full dose thrombolytics or combination therapy to
facilitate PCI are awaited. Until data from randomised
studies are available, firm recommendations on such
strategies cannot be made.
Facilitation with abciximab is so far the only recommenda-
tion based on published positive studies.
PCI
PCI in CABGs
Background
In patients with previous CABG, it is estimated that the rate
of MI is approximately 2–3% over the first five years, with
recurrent infarction in as many as 36% of patients at 10
years.103 104 In a study investigating primary PCI in patients
with AMI and prior CABG,104 previous CABG was associated
with reduced success compared with patients without prior
CABG; the success rate was lower still if the treated vessel
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was an SVG. The increased incidence of adverse cardiac
events appears to be largely caused by adverse baseline
clinical characteristics and inherent problems associated with
the treatment of degenerated vein grafts. SVGs have more no
reflow phenomena and reinfarct more frequently than native
vessels after PCI.
Recommendations
Considering the limited options available, PCI is a valid
therapeutic strategy in these patients. When dilating an SVG,
the use of distal protection devices or thrombectomy devices
may help prevent post-procedural events, such as no reflow
and cardiogenic shock.
Culprit vessel versus all vessel intervention
Background
While the patient is undergoing PCI for AMI, there is an
opportunity to treat all or several major coronary vessels, not
just the occluded vessel. Where there are waiting lists for
interventional procedures, speed of therapy and cost reduc-
tion issues may warrant this approach. In addition, the
anticoagulant effects of adjuvant pharmacological therapy
that the patient has received will be maintained during other
vessel intervention.
It should be noted that intervention in a non-culprit, non-
ischaemic patent vessel runs the risk of undue complications
in what is already a high risk situation. The ACC/AHA
guidelines on PCI give elective PCI of a non-infarct related
artery at the time of AMI a class III recommendation with a C
level of evidence (for definition see Smith et al8).
Before taking the decision to intervene in other vessels, the
haemodynamic status of the patient and the effect of
angioplasty on the suspected culprit vessel, resolution, or
not, of chest pain and ST segment elevation after a successful
angiographic procedure should be taken into account. In
contrast, in cases of cardiogenic shock, systematic interven-
tion in multiple vessels may be required to optimise
reperfusion of the heart.
Recommendations
Given the lack of conclusive supporting evidence, the
consensus among experts is that culprit only intervention
should be the recommended strategy. However, the panel
also believes that all accessible vessels should be treated in
patients with shock. Finally, if an experienced interventionist
feels that it is in the patient’s best interest (for example
during persistent chest pain, lack of ST segment resolution,
undetermined culprit vessel), multi-vessel PCI is not contra-
indicated on evidential grounds.
Cardiogenic shock
Background
Cardiogenic shock complicates 7–10% of AMI cases and is
associated with a 70–80% mortality rate.105 Early recognition
and aggressive treatment are both very important in these
patients. In addition, since the vast majority of patients
develop cardiogenic shock after hospital admission, the
assessment of predictors of shock appears to be of paramount
importance.
A study characterising the clinical factors predictive of
cardiogenic shock developing after thrombolytic therapy for
AMI found the major factors to be age, systolic blood
pressure, heart rate, and Killip class.106 Other important risk
factors have been identified including: sex, prior history of
MI, heart failure, or CABG, diabetes, and multi-vessel
disease.107 The absence of aspirin, angiotensin converting
enzyme (ACE) inhibitors or b blockers in the prescription was
also associated with worse outcomes.107
A trial evaluating the use of angioplasty, thrombolytic
therapy, emergency CABG, and support devices (such as
IABP counterpulsation, Hemopump insertion, and ventricu-
lar assist devices) in patients with AMI complicated by
cardiogenic shock found that the 30 day survival rate was
significantly better in patients who underwent successful
angioplasty of the infarct related artery than in patients with
failed angioplasty (61% v 7%; p = 0.002) or no attempt at
angioplasty (61% v 14%; p = 0.003).107 The GUSTO I trial
also found that in AMI patients who developed cardiogenic
shock, only angioplasty was associated with a significantly
lower mortality rate.108 This difference was maintained over
the one year follow up period. The only clinical variable that
predicted survival was age , 65 years. This was confirmed in
the larger, randomised SHOCK trial, which compared the
effect of early emergency revascularisation (ERV), within six
hours of randomisation, and initial medical stabilisation
(IMS) on 30 day, six month, and one year survival for
patients with AMI complicated by cardiogenic shock.109 At 30
days, there was no significant difference in the frequency of
the primary end point of overall mortality between the two
groups (46.7% in the ERV group v 56.0% in the IMS group).
However, the one year survival rate was 46.7% for patients in
the ERV group compared with 33.6% in the IMS group
(p , 0.03).110 The investigators recommended the rapid
transfer of AMI patients with cardiogenic shock, particularly
those aged , 75 years, to medical centres able to provide
early angiography and revascularisation procedures. The
benefit of coronary artery stenting combined with the
administration of abciximab in patients with cardiogenic
shock has recently been analysed in two non-randomised
studies.111 112 This association has resulted in higher proce-
dural TIMI grade 3 flow rates and better long term outcomes.
Recommendations
We recommend careful assessment of the risk of developing
cardiogenic shock in each patient (knowing the risk factors
for shock) in order to ensure early diagnosis and to allow
rapid transfer and adequate intervention. A more aggressive
approach is usually necessary in these patients, including
more frequent use of IABPs, inotropic drugs, and GpIIb/IIIa
inhibitors, as well as reperfusion that is as complete as
possible.
No reflow and myocardial blush below grade 3
Background
There is growing recognition that a patent infarct related
artery may not be sufficient to guarantee recovery of
myocardial perfusion, and that patency of the coronary
microcirculation is crucial.113 The persistence of abnormally
slow myocardial blood flow in the absence of angiographi-
cally significant obstruction, thrombus formation, or dissec-
tion, is termed no reflow (although it encompasses states of
no flow, as well as significantly impaired blood flow).114
Patients with no reflow have an increased risk of subsequent
MI and death.113 The mechanisms thought to be responsible
are: vasoconstriction and vasospasm; loss of capillary auto-
regulation; distal embolisation (of angiographically visible
vessels); microvascular plugging (vaso-occlusion of micro-
vessels linked to vasoconstrictive mediators, platelet/leuco-
cyte agreggates, inflammatory cytokines, endothelial
dysfunction); tissue oedema; or a combination of these
factors. No reflow affects 10–20% of patients undergoing
intervention following AMI.115 A study evaluating clinical
factors related to the development of no reflow after
successful coronary reperfusion in patients with AMI found
that, in those patients where no reflow developed, it was
related to the severity of myocardial damage (number of Q
waves), the size of the risk area, and the occlusion status of
the infarct related artery.115 Ischaemic preconditioning (pre-
infarction angina) appeared to attenuate no reflow.115
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Pharmacological treatment of no reflow and
diminished myocardial blush
Verapamil has been shown to be effective as a treatment for
both no reflow and slow flow in both retrospective,116 and
prospective117 studies. Intracoronary injection of verapamil
after PCI for AMI has been shown to attenuate microvascular
dysfunction and augment myocardial blood flow in patients
with AMI, leading to better functional outcomes than PCI
alone.118 However, the clinical benefit remains hypothetical.
Potential problems with verapamil include generation of
arrhythmias, LV depression, atrioventricular block, and the
development of shock. However, these have not been
observed in trials.117
A small trial assessing whether intracoronary papaverine, a
potent coronary microvascular dilator, could attenuate the no
reflow phenomenon after PCI found that it significantly
improved TIMI flow grade (only 15% of patients included
were AMI patients).118 Another study (in AMI patients)
investigated the effects of nitroprusside, a nitric oxide direct
donor, on no reflow. Nitric oxide is a potent vasodilator and is
important in controlling coronary blood flow through the
microcirculation. Nitroprusside led to a highly significant and
rapid improvement in angiographic flow and blood flow
velocity in patients with no reflow PCI.119
The potential role of adenosine in reducing infarct size in
patients with AMI was investigated in the AMISTAD study.120
Adenosine significantly reduced infarct size versus placebo
(33% relative reduction). However, there was no difference in
clinical outcomes, and, in fact, a trend towards more events
was observed in the adenosine arm. Of note, a small,
randomised study (54 patients) showed adenosine to reduce
the incidence of no reflow phenomena (4% v 26% in patients
receiving placebo).120
In the recently reported AMISTAD II study, anterior
infarction patients (n = 2118) were randomised to high
dose adenosine, low dose adenosine, or placebo, followed by
thrombolysis or PCI.120 Some effect of adenosine, limited to
the highest dose tested in this study, was seen on infarct size
but no significant difference was observed in clinical events
(death/heart failure at six months).121
Part of the efficacy of GpIIb/IIIa inhibitors is believed to
relate to direct effects on no reflow preventing distal
embolisation. It has been proposed that GpIIb/IIIa inhibitors
act on distal embolisation, platelet activation, and even
plugging inflammation. Results observed on flow in AMI
suggest that these drugs have a preventative effect.63
Interventional approaches to reduce no reflow or
diminished blush grade
Direct stenting data suggest that stenting without balloon
pre-dilatation may reduce the occurrence of no reflow.37
Limited data are available on the use of distal protection
devices in AMI.40–42 However, peripheral studies indicate that
such devices do protect against the risk of downstream
embolisation during percutaneous procedures.
Recommendations
Glyceryl trinitrate, verapamil, papaverine, nitroprusside, and
adenosine are frequently used to treat no reflow, although
there are few data to support the use of these drugs. They are
not recommended at this time. The best treatment for no
reflow is still undetermined. Prevention should be encour-
aged and, in this respect, data with GpIIb/IIIa inhibitors look
encouraging, as does the use of distal protection devices and
direct stenting.
The elderly patient
Background
Patients aged . 75 years constitute almost one third of all
AMI patients and this proportion is growing rapidly as the
global population ages.122 123 Elderly patients tend to have
non-compliant arteries, more extensive disease, and more
severe stenoses caused by an increased plaque load.
Advanced age is a risk factor for adverse outcomes in
patients with AMI,122 124 and elderly patients, especially those
aged . 80 years, are often excluded from studies.
The one year survival rate in octogenarian and older
patients is significantly less than in younger patients.124 125
The greater mortality in octogenarians is likely to be caused
by the increased incidence of cardiac risk factors, including
diabetes and hypertension, together with a greater frequency
of heart failure and three vessel disease. De Boer et al studied
a series of 87 patients aged . 75 years and concluded that
primary coronary angioplasty for AMI had a significant
clinical benefit when compared with intravenous streptoki-
nase treatment.126 These results suggest that primary PCI is
beneficial in the elderly, and that an early aggressive strategy
should be adopted for this age group.
A substudy of the GUSTO IIB trial investigated the effect of
age on outcome in patients randomised to receive primary
angioplasty or t-PA.124 Outcome was improved with angio-
plasty compared with t-PA in each 10 year patient group,
although risk increased with age irrespective of treatment.
Recommendations
Elderly patients are generally good candidates for angioplasty
(but not for thrombolysis) although the procedure is more
likely to be difficult in these patients.
POST-PCI
Length of hospital stay
Background
A substudy of the GUSTO I trial found that the hospitalisa-
tion of patients with uncomplicated AMI for . 3 days after
thrombolysis is uneconomical.127 128
The PAMI II trial investigated whether discharge from
hospital after three days is safe and cost effective in low risk
patients with AMI treated with PCI.129 Low risk patients (age
, 70 years, left ventricular ejection fraction (LVEF) . 45%,
one or two vessel disease, successful PCI, no persistent
arrhythmias) were randomised to receive accelerated care
(admission to a non-intensive care unit and day three
hospital discharge) or traditional care. Patients who received
accelerated care had similar in-hospital outcomes but were
discharged three days earlier and had lower hospital costs
than those who received traditional care. At six months,
accelerated and traditional care groups had similar mortality
rates and similar rates of adverse events (for example,
unstable ischaemia, reinfarction, stroke, and heart failure).128
Recommendations
Early discharge on the third day after optimal PCI for
uncomplicated AMI in low risk patients is recommended.
Early discharge is not recommended in higher risk patients or
following any complication or unsatisfactory procedure.
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